J&J to stop studies of depression drug due to low effectiveness
Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...
Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript
Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO ...